RecruitingPhase 2Phase 3NCT07204275
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy
Sponsor
Vertex Pharmaceuticals Incorporated
Enrollment
176 participants
Start Date
Sep 30, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria1
- Diagnosed with pMN with confirmatory historical biopsy. If no historical biopsy was performed that confirmed pMN, a biopsy can be performed during Screening to confirm eligibility
Exclusion Criteria1
- Hypersensitivity to investigational medicinal product or to any of its excipients
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPovetacicept
Solution for Subcutaneous Injection.
DRUGTacrolimus
Capsules for Oral Administration.
Locations(98)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07204275
Related Trials
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT06962800102 locations
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
NCT0655726519 locations
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
NCT0757174621 locations
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
NCT056684036 locations
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
NCT0647019121 locations